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Because dendritic cells (DCs) play a critical role in the regulation of adaptive immune
responses, they have been ideal candidates for cell-based immunotherapy of cancers and
infections in humans. Generally, monocyte-derived DCs (MDDCs) were generated from
puriﬁed monocytes by multiple steps of time-consuming physical manipulations for an
extended period cultivation. In this study, we developed a novel, simple and rapid method
for the generation of type-1 helper T cell (Th1)-stimulating human DCs directly from bulk
peripheral blood mononuclear cells (PBMCs). PBMCs were cultivated in the presence of
20 ng/ml of granulocyte-macrophage colony-stimulating factor, 20 ng/ml of interleukin-4
(IL-4) and 1,000 U/ml of interferon-β for 24 h followed by 24 h maturation with a cytokine
cocktail containing 10 ng/ml of tumor necrosis factor-α (TNF-α), 10 ng/ml of IL-1β and 1 μg/ml
of prostaglandin E2. The phenotype and biological activity of these new DCs for induction
of allogeneic T cell proliferation and cytokine production were comparable to those of the
MDDCs. Importantly, these new DCs pulsed with inactivated HIV-1 could generated HIV-1-
reactive CD4+ T cell responses in humanized mice reconstituted with autologous PBMCs
from HIV-1-negative donors.This simple and quick method for generation of functional DCs
will be useful for future studies on DC-mediated immunotherapies.
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INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting cells
(APCs) which play a critical role in the regulation of the adaptive
immune response through activation and polarization of naive
T cells (Banchereau et al., 2000). Since small numbers of acti-
vated DCs are highly efﬁcient in generating immune responses
against infections and cancers (Moll and Berberich, 2001; Stein-
man and Banchereau, 2007), the DC therapy represents a new
and promising immunotherapeutic approach for treatment of
advanced cancers as well as for prevention of infectious diseases.
Indeed, the current clinical trials with ex vivo-generated DCs (so-
called DC vaccine) will yield precious information regarding their
potentials as vectors for immunotherapy (Gilboa, 2007; Connolly
et al., 2008; Ezzelarab and Thomson, 2011). However, the general
protocols to generate DCs are complicated and time consuming.
Moreover, since different ex vivoDCgenerationmethods affect the
DC phenotype and function (Kalantari et al., 2011), it is critical
to choose appropriate method for generating functional DCs. In
general, the DC precursormonocytes are puriﬁed from PBMCs by
adherence (Jonuleit et al., 2001), elutriation (Berger et al., 2005)
or positive or negative selection using immunomagnetic beads
(Babatz et al., 2003). These enriched monocytes are then induced
to differentiate into DCs by 5 days-in vitro cultivation in medium
supplemented with granulocyte macrophage colony-stimulating
factor (GM-CSF) and interleukin (IL)-4 followed by a 2-days-
maturation procedure (Sallusto and Lanzavecchia, 1994; Gilboa,
2007; Dauer et al., 2008). However, a lines of evidence are increas-
ing that mature monocyte-derived DCs can be generated even
after short-term cell culture for 2–3 days (Dauer et al., 2003a,b;
Jarnjak-Jankovic et al., 2007; Zhang et al., 2008; Tawab et al., 2009).
In this study, in an attempt to simplify the methods currently
being used for optimal DC generation and to develop a stan-
dardized method of preparing effective myeloid DC vaccine for
immunotherapies, we explored the efﬁcacy of using unfraction-
ated PBMCs as a source of DC precursors and short-term in vitro
cell culture just for 2 days.
MATERIALS AND METHODS
REAGENTS
The media used were RPMI 1640 medium (Sigma, St. Louis, MO,
USA) supplemented with 10% fetal calf serum (FCS; Sigma, St.
Louis, MO, USA), 100 U of penicillin per ml, and 100 μg of
streptomycin per ml (hereafter called RPMImedium) and Iscove’s
modiﬁed Dulbecco’s medium (Lifetechnologies, Grand Island,
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NY, USA) supplemented with 10% FCS with the same antibi-
otics (hereafter called Iscove’s medium). Aldrithiol-2 (AT-2) and
low-endotoxin bovine serum albumin (BSA) was purchased from
Sigma (St. Louis, MO, USA). The recombinant human cytokines
used included IL-4, GM-CSF, TNF-α and IL-1β (PeproTech, Lon-
don, UK). Enzyme-linked immunosorbent assay (ELISA) kits for
the quantitation of human IFN-γ, human IL-4, human IL-10 and
human IL-12 (detecting IL-12 p75 heterodimer) were purchased
from Biolegend. The human monocyte negative isolation kits and
the human T cell isolation kits were purchased from Invitrogen
(Carlsbad, CA, USA). The human naive CD4+ T cell isolation kit
was purchased from Miltenyi Biotec (Gladbach, Germany). The
Vybrant CFDA SE Cell Tracer Kit was purchased from Invitrogen.
GENERATION OF DCs
Human PBMCs were isolated from heparinized peripheral blood
obtained from normal healthy adult volunteer donors by standard
density gradient centrifugation. Cells at the interface were col-
lected and washed three times in cold phosphate-buffered saline
(PBS) containing 0.1% low-endotoxin BSA and 2 mM Na2EDTA.
For select experiments, monocytes were puriﬁed from PBMCs
using the CD14+ monocyte negative isolation kit (Invitrogen,
Carlsbad, CA, USA). An aliquot of cells from each monocyte
preparation was examined by ﬂow cytometry and found to con-
tain>90%CD14+ cells. To obtain immatureMDDCs (iMDDCs),
PBMCs (2.5 × 106 cells/ml) or the puriﬁed monocytes (5 × 105
cells/ml) were cultured in RPMI medium containing 20 ng/ml of
human GM-CSF and 20 ng/ml of human IL-4 at 37◦C in 24-well
plates in a 5%CO2 humidiﬁed incubator for 5 days. In other exper-
iments, iDCs were generated from either puriﬁed monocytes or
whole PBMCs by cultivation in RPMI medium containing GM-
CSF (20 ng/ml), IL-4 (20 ng/ml) and IFN-β (1,000U/ml) for 1 day.
These iDCs were matured by incubation in the presence of either
10 ng/ml of LPS (Sigma) or a cocktail containing 10 ng/ml of TNF-
α, 10 ng/ml of IL-1β and 1 μg/ml of prostaglandin E2 (PGE2; TIP
cocktail) for 1–2 days.
FLOW CYTOMETRY
Aliquots of the cells to be analyzed were incubated in PBS contain-
ing 0.1%BSAand 0.1% sodiumazide (FACSbuffer) supplemented
with 2 mg/ml normal human IgG on ice for 15 min to block
Fc receptors. The cell suspension was then incubated with a
predetermined optimal concentration of the appropriate ﬂuo-
rescent dye-labeled mAbs against human cell surface markers on
ice for 30 min. The ﬂuorescent dye-labeled monoclonal antibod-
ies (mAbs) against human cell surface molecules used included
anti-CD3, anti-CD4, anti-CD8, anti-CD14, CD20, anti-CD80,
anti-HLA-DR, and isotype-matched control mAbs (Beckman
Coulter, Fullerton, CA, USA), and anti-CD11c, anti-CD86, and
anti-CD83 (BioLegend, San Diego, CA, USA). After washing with
FACS buffer, cells were ﬁxed in 1% paraformaldehyde (PFA) con-
taining FACSbuffer. The cellswere then analyzedonFACS-Calibur
ﬂow cytometer with CellQuest software (BD Pharmingen, San
Diego, CA,USA). Isotype-matchedmAbs were utilized as controls
to stain an aliquot of the cells to be analyzed for purposes of estab-
lishing gates and for determination of the frequency of positively
stained cells.
HIV-1 PREPARATION AND INACTIVATION
HIV-1IIIB (virus that only use CXCR4 as chemokine co-receptor,
termed X4) was harvested from Molt-4/IIIB cell cultures. Batches
of eachHIV-1 preparation were inactivated with Aldrithiol-2 (AT-
2; Sigma) as described previously (Yoshida et al., 2003). AT-2 was
removed by three successive ultraﬁltration in PBS using 100-kDa-
cut-off centrifugal ﬁltration devices (Centriprep 100; Amicon,
Beverly, MA, USA). Then AT-2–inactivated HIV-1 (iHIV) was
puriﬁed by pelleting down the virus at 20,000 × g for 2 h three
times in 0.1% BSA-PBS. The virus pellet was resuspended in 0.1%
BSA-PBS, aliquoted, and stored at −80◦C until use. The concen-
tration of HIV-1 was estimated by measuring levels of HIV-1 p24
antigen with our in-house p24 ELISA kit (Tanaka et al., 2010).
As previously described (Yoshida et al., 2003), activated human
PBMCs incubated with an aliquot of 1 μg/ml of the AT-2-treated
HIV-1 preparation failed to demonstrate the presence of any
detectable infectious virions (data not shown).
STIMULATION OF T CELLS
Enriched populations of naive CD4+ T cells and bulk T cells
with >90% purity were isolated from normal human PBMCs
by using appropriate negative cell isolation kits. These T cells
(4 × 104 cells/well) were ﬁrst labeled with carboxy-ﬂuorescein
diacetate succinimidyl ester (CFSE) according to the manu-
facturer’s instructions (Invitrogen, Carlsbad, CA, USA), then
co-cultured with allogeneic DCs at a T cells: DCs ratio of 50:1
in 100 μl of RPMI medium supplemented with 20 U/ml human
IL-2 in 96-well,U-bottomedplates. Cell proliferation and cytokine
production were determined on day 4.
hu-PBL-SCID MICE
The BALB/c-rag2−/−γc−/− mice lacking T cells, B cells and natu-
ral killer (NK) cells (Rag2−/− mice; Traggiai et al., 2004)were used
in this study. Themice were kept in the speciﬁc-pathogen-free and
P3 animal facilities of the Laboratory Animal Center, University of
the Ryukyus. The protocols for the care and use of mice engrafted
with human PBMCs and autologous DCs sensitized with inacti-
vatedHIV-1 or ovalbumin (OVA)were approved by the committee
on animal research of the University of the Ryukyus prior to ini-
tiation of the study. Matured DCs (5 × 105 cells) pulsed with
either AT-2-inactivated HIV-1 (40 ng of p24) or 100 μg of OVA in
100 μl of RPMI medium for 2 h at 37◦C were mixed with autol-
ogous fresh PBMCs (3 × 106 cells) in a ﬁnal volume of 100 μl
in serum-free RPMI medium, and the were directly injected into
the spleen of Rag2 mice as previously described (Yoshida et al.,
2003). One week later, the same number of DCs pulsed with the
same antigens were inoculated again into the spleen. One week
later, mice were sacriﬁced, blood was collected by cardiocente-
sis, and human CD4+ T cells were enriched from splenocytes
using a human CD4+ T cell isolation kit according to the man-
ufacturer’s instructions. For the measurement of antigen-speciﬁc
human cellular immune responses, human CD4+ T cell (2 × 105
cells) collected from the spleens of immunizedRag2−/− micewere
cultured for 2 days with autologous monocytes (2 × 105 cells) in
the presence or absence of inactivated HIV containing 40 ng/ml of
p24 in 500μl of RPMImedium supplemented with 20U/ml of IL-
2 in individual wells of a 48-well plate at 37◦C. The concentration
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of human IFN-γ or IL-4 produced in the culture supernatants was
determined with ELISA kits.
STATISTICAL ANALYSIS
Data were analyzed by Student’s t test with the with Prism software
(GraphPad Software Inc., San Diego, CA, USA).
RESULTS
GENERATION OF MYELOID MATURE DCs DIRECTLY FROM PBMCs
WITHIN 2 DAYS
In order to reduce the cost, labor and any loss of potential precur-
sors from PBMCs, we have previously established a novel culture
method for generating functional human DCs from unfrac-
tionated PBMC in which whole PBMCs were cultured in the
presence of IL-4 and GM-CSF for 5 days followed by a 2-day
maturation in media containing poly I:C and IL-1β (Kodama
et al., 2010). However, there were considerable lot variations
in commercial poly:IC in the DC-maturation activity (data not
shown). Therefore, we tested a previously reported matura-
tion cytokine cocktail containing TNF-α, IL-1β, IL-6 and PGE2
(Jonuleit et al., 1997). In a preliminary study, we found that IL-
6 was not necessary to mature DCs from puriﬁed monocytes
in the present cell culture conditions, probably due to the use
of serum-containing media. Thus, we used a cytokine cocktail
FIGURE 1 | Generation of functional human myeloid DCs directly
from PBMCs in vitro within 2 days. MDDCs generated puriﬁed
monocytes for 7 days (7-day-DC/Mo) or whole PBMCs cultured in
medium containing GM-CSF, IL-4 and IFN-β (2-day-DC/PBMC), either
non-treated or treated with the maturation cocktail containing TNF-α,
IL-1β and PGE2 (TIP) were examined for the expression of mature DC
markers by a ﬂow cytometry. Cells were stained with antibodies to
CD11c, CD14, CD83 and CD86, and analyzed on a subpopulation
gated for FSChigh, SSChigh and CD11c+. The percentages of the
positive cells in the gated population were shown in the dot plots.
Data shown are representative of three independent experiments using
blood from three different donors.
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containing 10 ng/ml of TNF-α, 10 ng/ml of IL-1β and 1 μg/ml
of PGE2 (hereafter called TIP cocktail) throughout the present
study.
Based on our previous report that monocytes can be differ-
entiated into mature DCs within 2 days (Zhang et al., 2008),
we tested whether Th1-inducing DCs could be generated from
unfractionated PBMCs. PBMCs (2.5 × 106 cells/ml) were cul-
tured in RPMI medium containing GM-CSF (20 ng/ml), IL-4
(20 ng/ml) and IFN-β (1,000 U/ml) for 1 day followed by addi-
tional 1 day cultivation in the presence or absence of the TIP
cocktail. The phenotypes of CD11c+ large cells in these 2-day
PBMC cultures were compared with those of MDDCs derived
from puriﬁed monocyte for 7 days (7-day-DC/Mo; Figure 1). The
proportion of FSChigh and SSChigh cells in the 2-day-DC/PBMC
culture was 20∼25% of total viable cells depending on donors
and these cells expressed CD11c (data not shown). After mat-
uration with the TIP cocktail, similar to the 7-day-DC/Mo, the
large CD11c+ cells in the 2-day PBMC cultures became CD14low,
CD86high and CD83high, a typical marker of maturedmyeloid DCs
(Ohshima et al., 1997). The other viable cell populations in the 2-
day PBMC cultures were CD3+ T cells (54.0∼59.2%), CD56+ NK
cells (8.4∼9.3%) and CD19+ B cells (6.5∼8.6%; n = 3). These
data showed that the present culture method was applicable to
generate myeloid mature DCs from bulk PBMCs within 2 days
(2-day-DC/PBMC).
Thenwe tested cytokine production by these 2-day-DC/PBMC.
Interestingly, in contrast to the DCs matured in the presence of
LPS, the production of IL-12 and IL-10 by the TIPmatured 2-day-
DC/P was minimum (Figure 2). To investigate whether the 2-day-
DC/PBMC were immunologically functional, we examined their
ability to stimulate allogeneic T cell proliferation. Like theMDDCs
(7-day-DC/Mo), the 2-day-DC/PBMC could stimulate allogeneic
T cell proliferation (Figure 3A). Then we quantitated the levels of
IFN-γ and IL-4 in the culture supernatants from allogeneic CD4+
T cells co-cultured with various DCs. As shown in Figure 3B,
among the four DC preparations including the 7-day-DC/Mo,
7-day-DCs from PBMCs (7-day-DC/PBMC), 2-day-DCs from
monocytes (2-day-DC/Mo) and 2-day-DC/PBMC, the 2-day-
DC/PBMC were most potent in induction of IFN-γ production.
The bulk 2-day-DC/PBMC alone did not produce detectable IFN-
γ (<20 pg/ml) in the present culture conditions (data not shown).
The levels of IL-4 and IL-10 were below detection (<5 pg/ml)
in all the samples tested (data not shown). These results indi-
cated that the 2-day-DC/PBMC had a potential to induce Th1
response.
INDUCTION OF HIV-1-REACTIVE HUMAN CD4+ T CELL RESPONSES IN
hu-PBL-SCID MICE
Finally, we examined whether the short-term generated 2-day-
DC/PBMCcould induceHIV-1-reactive immune responses in vivo
in comparison to MDDCs (7-day-DC/Mo) using our hu-PBL-
SCID mice model (Yoshida et al., 2003). SCID mice were intra-
splenically transplanted with DCs loaded with AT-2-inactivated
HIV-1 together with autologous fresh PBMCs. On day 7, these
mice were received an intra-splenic booster injection with simi-
larly prepared antigen-pulsed DCs. Seven days after the booster
injection, mice were sacriﬁced and examined for antigen-speciﬁc
human immune responses. Figure 4 showed that after in vitro
re-stimulation with autologous APCs pulsed with inactivated
HIV-1, enriched human CD4+ T cells from two out of three
mice immunized withMDDCs (7-day-DC/Mo) pulsed with HIV-
1 and those from three out of four mice immunized with
2-day-DC/PBMC pulsed with HIV-1 produced IFN-γ in antigen-
dependent way, indicating that the 2-day-DC/PBMC could induce
HIV-1 antigen-reactive human T responses in vivo as potent as
MDDCs. In the re-stimulated culture supernatants, no IL-4 or
IL-10 was detected (<5 pg/ml) using ELISA (data not shown). In
addition, no detectable antibodies against HIV-1 were detected
FIGURE 2 | Production of cytokines by the 2-day-DC/PBMC.The levels of
IL-12 (bioactive p70 heterodimer) and IL-10 in the supernatants from MDDCs
(7-d-DC/M) or 2-day-DC/PBMC (2-d-DC/P) either non-matured (iM) or matured
with LPS or theTIP cocktail were determined by ELISA. Data are mean ± SD
of triplicate cultures. *P < 0.05, ***P < 0.001. Data shown are representative
of three independent experiments using blood from two different donors.
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FIGURE 3 | High levels of production of IFN-γ by allogeneicT cells
stimulated with 2-day-DCs generated from PBMCs. Matured MDDCs
(7-day-DC/Mo) and 2-day-DCs generated from PBMCs (2-day-DC/PBMC)
were co-cultured with CFSE-labeled allogeneic CD4+ T cells at DC toT cell
ratio of 1:50 for 4 days. The cell number of DCs in 2-day-DC/PBMC was
manually counted using a Burker-Turk hemo-cytometer in which only large
cells were counted. (A) Percentages of proliferated cells were examined by
ﬂow cytometry. (B)The levels of IFN-γ produced in the supernatants were
quantitated by ELISA. In addition to the DCs shown in (A), MDDCs
generated from PBMCs for 7 days (7-d-DC/P) and 2-day-DCs generated
from puriﬁed monocytes (2-d-DC/M) were also tested. Data shown are
representative of three independent experiments using blood from two
different donors.
as determined by using a commercial Western blot assay kit
in plasma samples from all the DCs-HIV-1-immunized mice
(data not shown).
Altogether, these results demonstrated that human myeloid
DCs directly generated from PBMCs by the present short-term
cultivation method were potent in induction of functional Th1
responses both in vitro and in vivo.
DISCUSSION
In the present study, we have developed a novel, simple and rapid
protocol for generating Th1-stimulating human myeloid DCs
directly from unfractionated PBMCs. These 2-day-DC/PBMC
were potent in both stimulating allogeneic T cells in vitro and
inducing HIV-1-reactive Th1 responses in hu-PBL-SCID mice.
The use of whole PBMCs as DC precursors might reduce any loss
of monocytes in the step of puriﬁcation by adherence (Jonuleit
et al., 2001), elutriation (Berger et al., 2005) or positive or nega-
tive selection using immunomagnetic beads (Babatz et al., 2003).
One possible concern on using whole PBMCs was that the non-
monocyte cells, such as T, B or NK cells, in the PBMCs might
interfere with differentiation and function of DCs. However, in
the present study there was no obvious difference in DC mat-
uration and function between in PBMC and puriﬁed monocyte
cultures.
For the ﬁnal maturation, we used a cytokine cocktail contain-
ing TNF-α and IL-1β and PGE2 (TIP coctail). Simultaneous use
of these three reagents in TIP was essential for maturation of
DCs since use of the reagents either in single or in two combi-
nations failed to mature DCs (data not shown). In general, IL-6
that is included in the maturation cytokine cocktail TNF-α and
IL-1β and PGE2 to mature DCs was not necessary in the present
culture conditions. The reason remains to be studied, but it is
possible that IL-6 is required in serum-free culture conditions.
The present 2-day-DC/PBMC matured by TIP produced lower
IL-12 than those matured by LPS. Low levels production of IL-
12 might be ascribed to the use of PGE2 that inhibits bioactive
IL-12 heterodimer production (Kalinski et al., 2001; Kalim and
Groettrup, 2013). Despite of the low level production of IL-12, the
TIP-matured 2-day-DC/PBMC were potent in stimulating IFN-
γ, but not IL-4 or IL-10, production by allogeneic T cells. The
reason for higher potentials of 2-day-DC/PBMC to induce Th1
cells than MDDCs remains to be clariﬁed. It is speculated that
natural DCs contained in the 2-day-PBMC-derived DCs might
enhance the activation. Indeed, 2-day-DC/PBMC culture gener-
ated from CD14+ cell-depleted PBMCs were able to stimulate
allogeneic CD4+ T cells to a lesser extent (data not shown). How-
ever, we cannot clearly determine if the stimulation was mediated
by remaining monocytes. Further study is required to solve this
issue. Importantly, as the previous study (Yoshida et al., 2003),
the present study showed the induction of primary HIV-1-speciﬁc
human CD4+ T cell immune responses in hu-PBL-SCID mice
by DC-based immunization, demonstrating that the present 2-
day-PBMC-derived DCs might have a potential for clinical use
in DC-based immunization in humans against HIV-1. It was of
interest that the levels of IFN-γ production were higher in CD4+
T cells immunized with 2-day-DC/PBMC than those immu-
nized with 7-day-DC/Mo. It is possible that 2-day-DC/PBMC
could live longer than 7-day-DC/Mo in vivo to stimulate antigen-
speciﬁc CD4+ T cells. In addition, because myeloid DCs are
susceptible to HIV-1 infection (Knight et al., 1990), the use of
these IFN-β-treated DCs will be beneﬁcial for HIV-1-infected
individuals.
In conclusion, the present study provided a new method to
generate functional human myeloid DCs directly from PBMCs in
a short-term culture period. These DCs will be useful for stud-
ies exploring potentials of DC-based immunization for not only
infectious diseases but also cancers in vitro and in vivo.
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FIGURE 4 | Functional activity of the 2-days-DCs in hu-PBL-SCID mice.
Fresh autologous PBMCs from normal human donors were transferred into
the Rag2−/− mouse spleen together with autologous mature MDDCs
(7-day-DC/Mo) or 2-days-PBMC-derived DCs (2-day-D/PBMC) pulsed with no
antigen (no antigen) or AT-2-inactivated HIV-1 (40 ng of p24). On day 7 after
the ﬁrst transplantation, these mice were received an intra splenic booster
injection with similarly prepared DCs. Seven days after the booster injection,
mice were sacriﬁced and human CD4+ T cells were puriﬁed from
splenocytes. These CD4+ T cells were co-cultured with autologous APCs
(adherent PBMCs) in the presence or absence of antigens (restimulation) for
2 days at 37◦C. IFN-γ levels produced in the culture supernatants were
measured by ELISA. Data show mean ± SD of triplicate cultures. *P < 0.05,
**P < 0.01, ***P < 0.001. Data shown are representative of three
independent experiments using blood from two different donors.
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